Orange Biomed announced today that it commenced a U.S. launch as it looks to fill testing gaps for pre-diabetes and diabetes. Seoul, South Korea–based Orange Biomed operates out of Research Triangle Park, North Carolina in the U.S. The company currently has ongoing studies for its OBM rapid A1c test. It designed the glycated hemoglobin analyzer […]
Senseonics announces first pediatric 365-day CGM insertion
Senseonics (NYSE:SENS) announced that the first pediatric study participant received an Eversense 365-day CGM insertion. The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy […]
Dexcom, Abbott applaud Medicare expansion for CGMs
Dexcom (Nasdaq:DXCM) and Abbott (NYSE:ABT) both commended a change to Medicare policies that benefits continuous glucose monitor (CGM) users. Last month, the Centers for Medicare & Medicaid Services (CMS) published a final local coverage determination (LCD) expanding coverage for CGMs. The ruling has now gone into effect. CMS first published the LCD modifying coverage criteria for […]
Abbott breaks ground on FreeStyle Libre manufacturing plant in Ireland
Abbott (NYSE:ABT) today broke ground on a new FreeStyle Libre manufacturing facility in Kilkenny, Ireland. Jared Watkin, SVP for Abbott’s diabetes care business, shared the news of the groundbreaking in a LinkedIn post. In August 2022, Ireland announced Abbott’s plans to spend €440 million ($450 million) to expand its operations in Ireland. The investment included […]
Researchers use tiny drug delivery implant to treat tumors
Researchers at Houston Methodist Research Institute developed a tiny drug delivery device for addressing difficult-to-treat cancers. The researchers published their work in a paper in Advanced Science. They used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAB). The team calls the device a nanofluidic drug-eluting seed (NDES). With the device — […]
FDA clears reader for next-gen Abbott FreeStyle Libre 3
Abbott (NYSE:ABT) announced today that the FDA cleared a reader device for its FreeStyle Libre 3 continuous glucose monitoring (CGM) system. The FDA cleared Abbott’s next-generation FreeStyle Libre 3 in May 2022. Abbott designed FreeStyle Libre 3 as the smallest and thinnest CGM sensor in the world. The system constitutes the size of two stacked […]
Glooko inks partnership with insulin dosing software developer Hedia
Glooko announced that it entered into a global partnership with Hedia to integrate its technology into Glooko’s diabetes management platforms. The companies aim to provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutics. This combination could enhance access for those with type 1 and type 2 diabetes requiring bolus […]
This technology could enable time-released drug delivery
Bioengineers at Rice University developed a new technology for delivering drugs in a time-releasing manner. Kevin McHugh, corresponding author of a study about the technology, believes this could make missing doses of medicines and vaccines a thing of the past. McHugh and the Rice team saw their work published online in Advanced Materials. According to McHugh […]
Glytec unveils enhanced GlucoMetrics insulin management software
Glytec announced today that it unveiled the next evolution of GlucoMetrics to provide new insights into glycemic outcomes. The enhanced GlucoMetrics platform offers new analytics, dashboards and data visualizations for health systems and hospitals. Offering this enhanced visibility into glycemic outcomes helps hospitals as they prepare for new Centers for Medicare and Medicaid Services (CMS) […]
Novo Nordisk, Aspect Biosystems ink $75M deal for diabetes treatments
Aspect Biosystems and Novo Nordisk today announced a collaboration, development and license agreement around diabetes and obesity treatments. The agreement focuses on bioprinted tissue therapeutics designed to replace, repair or supplement the body’s biological functions. Novo Nordisk and Aspect aim to deliver a new class of disease-modifying treatments for diabetes and obesity. It leverages Aspect’s […]
